Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries
Summary Despite the advent of safe and highly effective COVID-19 vaccines1–4, pervasive inequities in global distribution persist5. In response, multinational partners have proposed programs to allocate vaccines to low- and middle-income countries (LMICs)6. Yet, there remains a substantial funding gap for such programs7. Further, the optimal vaccine supply is unknown and the cost-effectiveness of investments into global vaccination programs has not been described. We used a validated COVID-19 simulation model8 to project the health benefits and costs of reaching 20%-70% vaccine coverage in 91 LMICs. We show that funding 20% vaccine coverage over one year among 91 LMICs would prevent 294 million infections and 2 million deaths, with 26 million years of life saved at a cost of US$6.4 billion, for an incremental cost effectiveness ratio (ICER) of US$250/year of life saved (YLS). Increasing vaccine coverage up to 50% would prevent millions more infections and save hundreds of thousands of additional lives, with ICERs below US$8,000/YLS. Results were robust to variations in vaccine efficacy and hesitancy, but were more sensitive to assumptions about epidemic pace and vaccination costs. These results support efforts to fund vaccination programs in LMICs and complement arguments about health equity9, economic benefits10, and pandemic control11..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 04. Mai Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Siedner, Mark J. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2021.04.28.21256237 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI020489625 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI020489625 | ||
| 003 | DE-627 | ||
| 005 | 20230429095038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210505s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.04.28.21256237 |2 doi | |
| 035 | |a (DE-627)XBI020489625 | ||
| 035 | |a (DE-599)biorXiv10.1101/2021.04.28.21256237 | ||
| 035 | |a (biorXiv)10.1101/2021.04.28.21256237 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Siedner, Mark J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary Despite the advent of safe and highly effective COVID-19 vaccines1–4, pervasive inequities in global distribution persist5. In response, multinational partners have proposed programs to allocate vaccines to low- and middle-income countries (LMICs)6. Yet, there remains a substantial funding gap for such programs7. Further, the optimal vaccine supply is unknown and the cost-effectiveness of investments into global vaccination programs has not been described. We used a validated COVID-19 simulation model8 to project the health benefits and costs of reaching 20%-70% vaccine coverage in 91 LMICs. We show that funding 20% vaccine coverage over one year among 91 LMICs would prevent 294 million infections and 2 million deaths, with 26 million years of life saved at a cost of US$6.4 billion, for an incremental cost effectiveness ratio (ICER) of US$250/year of life saved (YLS). Increasing vaccine coverage up to 50% would prevent millions more infections and save hundreds of thousands of additional lives, with ICERs below US$8,000/YLS. Results were robust to variations in vaccine efficacy and hesitancy, but were more sensitive to assumptions about epidemic pace and vaccination costs. These results support efforts to fund vaccination programs in LMICs and complement arguments about health equity9, economic benefits10, and pandemic control11. | ||
| 700 | 1 | |a Alba, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Fitzmaurice, Kieran P. |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Rebecca F. |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Justine A. |e verfasserin |4 aut | |
| 700 | 1 | |a Shebl, Fatma M. |e verfasserin |4 aut | |
| 700 | 1 | |a Ciaranello, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, Krishna P. |e verfasserin |4 aut | |
| 700 | 1 | |a Freedberg, Kenneth A. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 04. Mai |
| 773 | 1 | 8 | |g year:2021 |g day:04 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.04.28.21256237 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 04 |c 05 | ||
| 953 | |2 045F |a 570 | ||